The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model

A. Gibbons, D. Padilla-Carlin, C. Kelly, A.J. Hickey, Clifford Taggart, N.G. McElvaney, S.A. Cryan

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.
Original languageEnglish
Pages (from-to)2233-2245
Number of pages13
JournalPharmaceutical Research
Volume28 (9)
Issue number9
DOIs
Publication statusPublished - Sep 2011

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Organic Chemistry
  • Molecular Medicine
  • Pharmacology (medical)
  • Biotechnology
  • Pharmacology

Fingerprint Dive into the research topics of 'The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model'. Together they form a unique fingerprint.

Cite this